{"id":37932,"date":"2022-10-05T02:06:24","date_gmt":"2022-10-05T02:06:24","guid":{"rendered":"https:\/\/thepatientinvestor.com\/?p=37932"},"modified":"2022-10-05T02:08:52","modified_gmt":"2022-10-05T02:08:52","slug":"appen-ltd-apx","status":"publish","type":"post","link":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/","title":{"rendered":"Appen Ltd (APX)"},"content":{"rendered":"<table border=\"0\" summary=\"Current Price and Fair Value Estimate\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>Stock:<\/td>\n<td colspan=\"3\"><strong>Appen Ltd<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Exchange:<\/td>\n<td>ASX<\/td>\n<td>Symbol:<\/td>\n<td><strong>APX<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>05-Oct-22<\/td>\n<td>Latest price:<\/td>\n<td><strong>A$3.29<br \/>\n<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Market Cap:<\/td>\n<td>$406 m<\/td>\n<td>Fair Value:<\/td>\n<td><strong>A$2.99<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Forward DY:<\/td>\n<td>3.16%<\/td>\n<td>Payback (Years):<\/td>\n<td>N\/A<\/td>\n<\/tr>\n<tr>\n<td>Financial Y\/E:<\/td>\n<td>31-Dec-22<\/td>\n<td>Rating:<\/td>\n<td><strong>HOLD<\/strong><\/td>\n<\/tr>\n<tr>\n<td>Sector:<\/td>\n<td>Technology<\/td>\n<td>Industry:<\/td>\n<td>IT Services<\/td>\n<\/tr>\n<tr>\n<td>Investment Theme:<\/td>\n<td>Technology<\/td>\n<td>Macro Trends:<\/td>\n<td>A.I.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Summary<\/h2>\n<p>Appen (APX) is trading at a discount to our estimate of fair value. Our recommendation is HOLD in the current bear market.<\/p>\n<h2>Valuation<\/h2>\n<p>We reduced our fair value estimate for Appen (APX) by 74%, to A$2.99 per share, based on the following projections:<\/p>\n<ul>\n<li>real organic long-term growth of zero (formerly 15%);<\/li>\n<li>EBITDA margin of 12% (formerly 15%);<\/li>\n<li>capital expenditure of 5.2% of revenue (formerly 5.4%);<\/li>\n<li>working capital of 0.4% of revenue (formerly 0.6%); and<\/li>\n<li>an effective tax rate of 25%.<\/li>\n<\/ul>\n<p>We selected a payback period of 10 years to reflect the company&#8217;s small cap size and a competitive industry.<\/p>\n<h2>Business Profile<\/h2>\n<p>Appen provides quality data solutions and services for machine learning and artificial intelligence applications for technology companies, auto manufacturers and government agencies. The company&#8217;s business segments are Relevance; Speech &amp; Image and Others. Relevance generates the most revenue, providing annotated data used in search technology for improving the relevance and accuracy of search engines, social media applications, and e-commerce. Geographically, the majority of revenue is derived from the USA.<\/p>\n<h3>Performance<\/h3>\n<p>&#8220;Appen&#8217;s half year results reflect lower earnings due to challenging external operating and macro conditions, resulting in weaker digital advertising demand and a slowdown in spending by some major customers&#8230;&#8221; (1H FY22)<\/p>\n<p>FY22 EBITDA margin is expected to be materially lower than FY21.<\/p>\n<h3>Capital structure<\/h3>\n<p>APX has net cash (after deducting capitalized leases) of $33 million.<\/p>\n<h4>Disclosure<\/h4>\n<p>Staff of The Patient Investor may directly or indirectly own shares in the above company.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stock: Appen Ltd Exchange: ASX Symbol: APX Date: 05-Oct-22 Latest price: A$3.29 Market Cap: $406 m Fair Value: A$2.99 Forward DY: 3.16% Payback (Years): N\/A Financial Y\/E: 31-Dec-22 Rating: HOLD Sector: Technology Industry: IT Services Investment Theme: Technology Macro Trends: A.I. Summary Appen (APX) is trading at a discount to our estimate of fair value. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Appen Ltd (APX)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[3799],"tags":[5658],"class_list":["post-37932","post","type-post","status-publish","format-standard","hentry","category-pvt-australia","tag-appen-ltd-apx"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Appen Ltd (APX) - the patient investor<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Appen Ltd (APX) - the patient investor\" \/>\n<meta property=\"og:description\" content=\"Stock: Appen Ltd Exchange: ASX Symbol: APX Date: 05-Oct-22 Latest price: A$3.29 Market Cap: $406 m Fair Value: A$2.99 Forward DY: 3.16% Payback (Years): N\/A Financial Y\/E: 31-Dec-22 Rating: HOLD Sector: Technology Industry: IT Services Investment Theme: Technology Macro Trends: A.I. Summary Appen (APX) is trading at a discount to our estimate of fair value. &hellip; Continue reading &quot;Appen Ltd (APX)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/\" \/>\n<meta property=\"og:site_name\" content=\"the patient investor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61572934660810\" \/>\n<meta property=\"article:author\" content=\"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-05T02:06:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-05T02:08:52+00:00\" \/>\n<meta name=\"author\" content=\"Colin Twiggs\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Colin Twiggs\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/\"},\"author\":{\"name\":\"Colin Twiggs\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\"},\"headline\":\"Appen Ltd (APX)\",\"datePublished\":\"2022-10-05T02:06:24+00:00\",\"dateModified\":\"2022-10-05T02:08:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/\"},\"wordCount\":278,\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"keywords\":[\"Appen Ltd (APX)\"],\"articleSection\":[\"PVT Australian Portfolio\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/\",\"name\":\"Appen Ltd (APX) - the patient investor\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\"},\"datePublished\":\"2022-10-05T02:06:24+00:00\",\"dateModified\":\"2022-10-05T02:08:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/2022\\\/10\\\/05\\\/appen-ltd-apx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/thepatientinvestor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Appen Ltd (APX)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#website\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"name\":\"The Patient Investor\",\"description\":\"Smart. Strategic. Unfiltered. \",\"publisher\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thepatientinvestor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#organization\",\"name\":\"The Patient Investor Pty Ltd\",\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/thepatientinvestor.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1\",\"width\":250,\"height\":250,\"caption\":\"The Patient Investor Pty Ltd\"},\"image\":{\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61572934660810\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thepatientinvestor.com\\\/#\\\/schema\\\/person\\\/d42b18d516a80149d739845749ac6454\",\"name\":\"Colin Twiggs\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g\",\"caption\":\"Colin Twiggs\"},\"description\":\"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He founded PVT Capital (AFSL number 546090), which provides income and growth strategies to wholesale clients. Colin also co-founded Incredible Charts and writes the popular Patient Investor newsletter. Using a top-down approach, Colin identifies macro trends in the global economy and then combines fundamental and technical analysis to evaluate opportunities in sectors that stand to benefit. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\\\/2009 and 2020 bear markets well ahead of actual events.\",\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/people\\\/The-Patient-Investor\\\/61572934660810\\\/\",\"https:\\\/\\\/www.instagram.com\\\/colin_thepatientinvestor\",\"https:\\\/\\\/au.linkedin.com\\\/in\\\/colintwiggs\"],\"url\":\"https:\\\/\\\/thepatientinvestor.com\\\/index.php\\\/author\\\/investor\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Appen Ltd (APX) - the patient investor","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Appen Ltd (APX) - the patient investor","og_description":"Stock: Appen Ltd Exchange: ASX Symbol: APX Date: 05-Oct-22 Latest price: A$3.29 Market Cap: $406 m Fair Value: A$2.99 Forward DY: 3.16% Payback (Years): N\/A Financial Y\/E: 31-Dec-22 Rating: HOLD Sector: Technology Industry: IT Services Investment Theme: Technology Macro Trends: A.I. Summary Appen (APX) is trading at a discount to our estimate of fair value. &hellip; Continue reading \"Appen Ltd (APX)\"","og_url":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/","og_site_name":"the patient investor","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61572934660810","article_author":"https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","article_published_time":"2022-10-05T02:06:24+00:00","article_modified_time":"2022-10-05T02:08:52+00:00","author":"Colin Twiggs","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Colin Twiggs","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/#article","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/"},"author":{"name":"Colin Twiggs","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454"},"headline":"Appen Ltd (APX)","datePublished":"2022-10-05T02:06:24+00:00","dateModified":"2022-10-05T02:08:52+00:00","mainEntityOfPage":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/"},"wordCount":278,"publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"keywords":["Appen Ltd (APX)"],"articleSection":["PVT Australian Portfolio"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/","url":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/","name":"Appen Ltd (APX) - the patient investor","isPartOf":{"@id":"https:\/\/thepatientinvestor.com\/#website"},"datePublished":"2022-10-05T02:06:24+00:00","dateModified":"2022-10-05T02:08:52+00:00","breadcrumb":{"@id":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/thepatientinvestor.com\/index.php\/2022\/10\/05\/appen-ltd-apx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/thepatientinvestor.com\/"},{"@type":"ListItem","position":2,"name":"Appen Ltd (APX)"}]},{"@type":"WebSite","@id":"https:\/\/thepatientinvestor.com\/#website","url":"https:\/\/thepatientinvestor.com\/","name":"The Patient Investor","description":"Smart. Strategic. Unfiltered. ","publisher":{"@id":"https:\/\/thepatientinvestor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thepatientinvestor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/thepatientinvestor.com\/#organization","name":"The Patient Investor Pty Ltd","url":"https:\/\/thepatientinvestor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","contentUrl":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2026\/03\/cropped-cropped-patience-bg-1-inverted-400x400-1.png?fit=250%2C250&ssl=1","width":250,"height":250,"caption":"The Patient Investor Pty Ltd"},"image":{"@id":"https:\/\/thepatientinvestor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61572934660810","https:\/\/www.instagram.com\/colin_thepatientinvestor"]},{"@type":"Person","@id":"https:\/\/thepatientinvestor.com\/#\/schema\/person\/d42b18d516a80149d739845749ac6454","name":"Colin Twiggs","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/29a4e13250381b203ea835108c2d5eee4947439713c271ae5ba60afb53194432?s=96&d=mm&r=g","caption":"Colin Twiggs"},"description":"Colin Twiggs is a former investment banker with almost 40 years of experience in financial markets. He founded PVT Capital (AFSL number 546090), which provides income and growth strategies to wholesale clients. Colin also co-founded Incredible Charts and writes the popular Patient Investor newsletter. Using a top-down approach, Colin identifies macro trends in the global economy and then combines fundamental and technical analysis to evaluate opportunities in sectors that stand to benefit. Focusing on interest rates and financial market liquidity as primary drivers of the economic cycle, he warned of the 2008\/2009 and 2020 bear markets well ahead of actual events.","sameAs":["https:\/\/facebook.com\/people\/The-Patient-Investor\/61572934660810\/","https:\/\/www.instagram.com\/colin_thepatientinvestor","https:\/\/au.linkedin.com\/in\/colintwiggs"],"url":"https:\/\/thepatientinvestor.com\/index.php\/author\/investor\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p9tQ4n-9RO","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":16811,"url":"https:\/\/thepatientinvestor.com\/index.php\/2018\/08\/08\/appen-limited-apx\/","url_meta":{"origin":37932,"position":0},"title":"Appen Limited (APX)","author":"Colin Twiggs","date":"August 8, 2018","format":false,"excerpt":"Stock: Appen Limited Symbol: APX Exchange: ASX Appen was added to the ASX 200 in June 2018 and displays strong performance in both LT technical and revenue & earnings growth. Despite this, we have not added APX to our model portfolio, or issued a buy signal, because of its market\u2026","rel":"","context":"In &quot;Australia &amp; NZ&quot;","block_context":{"text":"Australia &amp; NZ","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/countries-regions\/australia-nz-countries-regions\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":29844,"url":"https:\/\/thepatientinvestor.com\/index.php\/2021\/12\/10\/australian-growth-performance-at-30-november-2021\/","url_meta":{"origin":37932,"position":1},"title":"Australian Growth: Performance at Nov-2021","author":"Andy","date":"December 10, 2021","format":false,"excerpt":"Australian Growth portfolio performance since inception on 1 July 2018 is set out below. We expect to hold most growth stocks for 5 to 10 years. Individual Stocks The portfolio has a sizable allocation to gold & precious metals (17% at 30-Nov-2021). We expect rising inflation and increasingly negative real\u2026","rel":"","context":"In &quot;PVT Australian Performance&quot;","block_context":{"text":"PVT Australian Performance","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-australian-performance\/"},"img":{"alt_text":"Australian Growth Annualized Performance 1-Jul-2018 to 30-Nov-2021: Portfolio 4.99%, ASX 200 Accumulation Index 8.79%","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/12\/perf-2021-11-aus.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/12\/perf-2021-11-aus.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2021\/12\/perf-2021-11-aus.png?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":41485,"url":"https:\/\/thepatientinvestor.com\/index.php\/2023\/04\/03\/australian-growth-performance-mar-2023\/","url_meta":{"origin":37932,"position":2},"title":"Australian Growth: Performance Mar-2023","author":"Andy","date":"April 3, 2023","format":false,"excerpt":"Australian Growth portfolio performance since inception on July 1, 2018 is set out below. We expect to hold most growth stocks for 5 to 10 years. Individual Stocks Past Performance Hypothetical $1 million invested in the Australian Growth portfolio on July 1, 2018: Performance Notes: Performance is calculated in Australian\u2026","rel":"","context":"In &quot;PVT Australian Performance&quot;","block_context":{"text":"PVT Australian Performance","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-australian-performance\/"},"img":{"alt_text":"Australian Growth Past Allocations","src":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/thepatientinvestor.com\/wp-content\/uploads\/2023\/04\/allocations-2023-03-aus-history.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":19620,"url":"https:\/\/thepatientinvestor.com\/index.php\/2020\/01\/15\/asx-leading-sectors\/","url_meta":{"origin":37932,"position":3},"title":"ASX Leading Sectors","author":"Colin Twiggs","date":"January 15, 2020","format":false,"excerpt":"The ASX 200 broke resistance at 6800, signaling a fresh advance. Expect retracement to test the new support level. Respect would strengthen the bull signal, confirming a fresh advance. At the same time, fundamentals are distinctly bearish, with falling retail sales and dwindling GDP growth. So, what sectors are driving\u2026","rel":"","context":"In &quot;Australia &amp; NZ&quot;","block_context":{"text":"Australia &amp; NZ","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/countries-regions\/australia-nz-countries-regions\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":18264,"url":"https:\/\/thepatientinvestor.com\/index.php\/2019\/05\/24\/xero-deep-in-overvalued-territory-xro\/","url_meta":{"origin":37932,"position":4},"title":"Xero deep in overvalued territory (XRO)","author":"Colin Twiggs","date":"May 24, 2019","format":false,"excerpt":"From Morningstar today: \"Cloud-based accounting software firm Xero has booked a strong result but the WAAAX club member remains deep in overvalued territory, says Morningstar. Xero this week reported a solid first half 2019 result, which included a 36 per cent boost in revenue and a 31 per cent jump\u2026","rel":"","context":"In &quot;PVT Australian Portfolio&quot;","block_context":{"text":"PVT Australian Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-australia\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":37620,"url":"https:\/\/thepatientinvestor.com\/index.php\/2022\/09\/20\/hub24-ltd-hub-2\/","url_meta":{"origin":37932,"position":5},"title":"Hub24 Ltd (HUB)","author":"Colin Twiggs","date":"September 20, 2022","format":false,"excerpt":"Stock: Hub24 Ltd Exchange: ASX Symbol: HUB Date: 20-Sep-22 Latest price: A$22.58 Market Cap: $1.8 bn Fair Value: 15.49 Forward DY: 1.12% Payback (Years): 12 Financial Y\/E: 30-Jun-22 Rating: HOLD Sector: Financial Industry: Capital Markets Investment Theme: LT Growth Macro Trends: Digital Growth Summary Hub24 Ltd (HUB) is trading at\u2026","rel":"","context":"In &quot;PVT Australian Portfolio&quot;","block_context":{"text":"PVT Australian Portfolio","link":"https:\/\/thepatientinvestor.com\/index.php\/category\/investment-allocation\/pvt-australia\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/37932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/comments?post=37932"}],"version-history":[{"count":3,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/37932\/revisions"}],"predecessor-version":[{"id":37935,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/posts\/37932\/revisions\/37935"}],"wp:attachment":[{"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/media?parent=37932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/categories?post=37932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thepatientinvestor.com\/index.php\/wp-json\/wp\/v2\/tags?post=37932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}